Latest news with #TurnTherapeutics
Time Business News
09-07-2025
- Health
- Time Business News
Breakthrough Innovations Transforming Eczema Therapeutics
Eczema therapeutics refer to the range of medical remedies and interventions designed to manage and relieve symptoms of eczema, which is a chronic inflammatory skin condition characterized by itching, redness, dryness and irritation. Eczema therapeutics are rapidly expanding in the market, which is powered by factors such as pollution, lifestyle changes and increased chemical risk due to the increasing proliferation of eczema. Development of advanced treatments, especially dupilumab such as biologics that target specific immune routes, are more effective and improve patient results with personal care. Additionally, more awareness, better healthcare access, and strong infrastructure are further enhancing market development. Key Growth Drivers and Opportunities Rise of Telemedicine and Mobile Health Apps: Eczema therapeutics are promoting the market by improving access to care, especially for patients in remote or underserved areas by improving access to care. These digital tools enable virtual consultation, real-time skin monitoring and individual treatment adjustment without in-tradition visit. They also support symptoms tracking, education and adherence to treatment through reminder, encouraging frequent care. This change for digital health increases the results and engagement of the patient when opening new channels to manage and distribute driving market growth, driving market growth. Challenges Eczema therapeutics faces several borders, including high cost of advanced treatments such as biologics, which can restrict access to many patients. Additionally, variability and potential side effects in the patient's response to therapy face challenges for effective management. Limited awareness in low income areas, lack of long -term treatment, and the root cause of treatment, instead of treatment, also obstructs market growth on symptomatic relief. Regulatory obstacles and slow approval procedures for new drugs carry forward innovation and availability. Innovation and Expansion Nektar Therapeutics Reveals Groundbreaking Eczema Therapy Following 'New Biology' Discovery In June 2025, After the biotech firm met all of its targets in a mid-stage study of its eczema medication, Nektar Therapeutics (NKTR) launched by triple digits. In order to treat inflammatory skin diseases and other autoimmune problems, Nektar has developed a novel biology and capitalized on the potential of regulatory T cell proliferators as a significant therapeutic approach. Three subcutaneous injections of Nektar's medication, rezpegaldesleukin, were administered to research participants. According to the Eczema Area and Severity Index, or EASI, patients' symptoms improved by 53% to 61% after 16 weeks. In contrast, the placebo group saw an improvement of 31%. As the Eczema Trial Draws to a Close, Turn Therapeutics Launches its Last Round of Crowdfunding and Collaborates with Clear Street on Public Market Strategies In April 2025, In addition to the impending start of a controlled clinical trial assessing its flagship, non-steroidal topical platform in patients with moderate to severe eczema, Turn Therapeutics, a clinical-stage biotechnology company that is leading the way in next-generation topical therapies, announced the opening of its final crowdfund investment round. As part of a larger strategic funding plan to finance late-stage studies throughout its therapeutic pipeline, Turn has also enlisted Clear Street to evaluate routes to the public markets. Over the course of an eight-week treatment period, Turn's forthcoming trial will evaluate the therapeutic performance of its unique mix, tracking decreases in itching and disease severity. Inventive Sparks, Expanding Markets Prominent players working in the eczema therapeutics manufacturing include Sanofi, Regeneron Pharmaceuticals Inc., Almirall, SA, UCB SA, NT-MDT SI and others. Investing in R&D to create sequential and targeted treatment, expanding market access through partnerships and digital health platforms, raising awareness and starting education campaigns to increase diagnosis rates, and to increase strength and access through partnership with payments with payments and healthcare providers around the world are important development strategies for all important development strategies for all important development strategies. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
02-04-2025
- Business
- Yahoo
Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets
LOS ANGELES, April 02, 2025--(BUSINESS WIRE)--Turn Therapeutics, a clinical-stage biotechnology company pioneering next-generation topical therapies, today announced the launch of its final crowdfund investment round in tandem with the upcoming initiation of a controlled clinical trial evaluating its flagship, non-steroidal topical platform in patients with moderate to severe eczema. Turn has also engaged Clear Street to assess pathways to the public markets as part of a broader strategic capital plan to fund late-stage trials across its therapeutic pipeline. "We are entering one of the most exciting and consequential chapters in Turn's history," said Bradley Burnam, CEO of Turn Therapeutics. "With our final crowdfunding round, everyday investors have a rare opportunity to deploy capital just before major clinical readouts -- and before we take on significant institutional funding." Turn's upcoming trial will assess the clinical performance of its proprietary formula over an eight-week treatment period, measuring reductions in disease severity and itch. The study will include a placebo control and is designed to build upon previously reported data demonstrating the formula's inhibition of IL-31 and IL-36 -- cytokines recognized as central drivers of the eczema disease process. Turn anticipates topline data by the end of 2025. In addition to supporting future phase 3 trials for its moderate to severe eczema candidate, proceeds from this fundraising round will advance Turn's research program for onychomycosis, or toenail fungus. Turn has previously secured post-public financing commitments through a $75 million equity facility with GEM, a private equity and alternative investment group. "These investment opportunities like ours are traditionally only available to venture capital funds and the ultra wealthy," Burnam said. "We believe this model -- combining grassroots investment with the support of bigger institutions -- is the future of biotech financing." The crowdfund campaign is now live here. More information on Turn's clinical programs can be found at For more information or to request an interview with Turn Therapeutics CEO Bradley Burnam, please contact Cooper Rumrill at (202) 980-4968 or cooper@ About Turn Therapeutics Turn Therapeutics is a pharmaceutical and medical device organization specializing in the development of advanced wound and dermatology solutions. Utilizing its proprietary technology and patient-first approach, Turn Therapeutics addresses critical needs in healthcare, aiming to improve access, outcomes, and quality of life. Visit to learn more about the company. The Regulation A+ offering is made available through StartEngine Primary LLC, member FINRA/SIPC. The investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of entire investment. The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements. View source version on Contacts Cooper Rumrill(202) 980-4968cooper@ Sign in to access your portfolio
